Alto Neuroscience, Inc. (NYSE:ANRO) Given Consensus Rating of “Moderate Buy” by Brokerages

Alto Neuroscience, Inc. (NYSE:ANRO) has been given a consensus recommendation of “Moderate Buy” by the seven brokerages that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $34.3333.

Several equities analysts recently issued reports on the company. Wedbush raised their price target on Alto Neuroscience from $13.00 to $22.00 and gave the company a “neutral” rating in a report on Tuesday, March 17th. Robert W. Baird boosted their price objective on Alto Neuroscience from $22.00 to $41.00 and gave the stock an “outperform” rating in a report on Wednesday, March 18th. Wall Street Zen downgraded shares of Alto Neuroscience from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Weiss Ratings reiterated a “sell (e+)” rating on shares of Alto Neuroscience in a research report on Monday, December 29th. Finally, Chardan Capital reissued a “buy” rating and set a $30.00 price target on shares of Alto Neuroscience in a research note on Tuesday, March 17th.

Institutional Trading of Alto Neuroscience

Several institutional investors and hedge funds have recently made changes to their positions in the business. AQR Capital Management LLC acquired a new position in shares of Alto Neuroscience in the 1st quarter valued at $52,000. Torren Management LLC acquired a new stake in shares of Alto Neuroscience during the fourth quarter worth $62,000. Invesco Ltd. acquired a new stake in shares of Alto Neuroscience during the first quarter worth $67,000. Vanguard Personalized Indexing Management LLC increased its holdings in Alto Neuroscience by 13.7% in the third quarter. Vanguard Personalized Indexing Management LLC now owns 17,045 shares of the company’s stock valued at $69,000 after purchasing an additional 2,055 shares during the last quarter. Finally, Bridgeway Capital Management LLC increased its holdings in Alto Neuroscience by 85.9% in the second quarter. Bridgeway Capital Management LLC now owns 54,100 shares of the company’s stock valued at $119,000 after purchasing an additional 25,000 shares during the last quarter.

Alto Neuroscience Stock Down 2.7%

NYSE:ANRO opened at $19.95 on Tuesday. The stock’s fifty day moving average price is $18.87 and its two-hundred day moving average price is $14.44. Alto Neuroscience has a 52-week low of $1.60 and a 52-week high of $25.17. The company has a debt-to-equity ratio of 0.12, a quick ratio of 15.69 and a current ratio of 15.69. The company has a market cap of $637.37 million, a price-to-earnings ratio of -9.15 and a beta of 2.51.

Alto Neuroscience (NYSE:ANRO) last released its earnings results on Monday, March 16th. The company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.11. On average, analysts anticipate that Alto Neuroscience will post -2.54 EPS for the current year.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.